Gilead Sciences (GILD) Accounts Payables (2009 - 2026)
Gilead Sciences' (GILD) quarterly Accounts Payables came in at $645.0 million in Q1 2026, down 12.48% YoY from $737.0 million in Q1 2025, and down 9.79% on a QoQ basis from $715.0 million in Q4 2025.
Gilead Sciences (GILD) Accounts Payables (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Accounts Payables data on file, last reported at $645.0 million in Q1 2026.
- Quarterly Accounts Payables fell 12.48% year-over-year to $645.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $645.0 million (down 12.48% YoY) and the FY2025 annual result came in at $715.0 million, down 14.17% from the prior year.
- Accounts Payables eased to $645.0 million in Q1 2026, from $715.0 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $905.0 million in Q4 2022 to a low of $537.0 million in Q2 2024.
- A 5-year average of $672.6 million and a median of $622.0 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables tumbled 39.23% — and 2024, when it jumped 54.1%.
- Tracing GILD's Accounts Payables over 5 years: stood at $905.0 million in 2022, then plunged by 39.23% to $550.0 million in 2023, then surged by 51.45% to $833.0 million in 2024, then decreased by 14.17% to $715.0 million in 2025, then fell by 9.79% to $645.0 million in 2026.
- The last three Accounts Payables figures came in at $645.0 million (Q1 2026), $715.0 million (Q4 2025), and $808.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.77 Bn | 632.01 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.90 Bn | 463.33 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 377.04 Bn | 369.90 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.08 Bn | 295.39 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.74 Bn | 252.84 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 236.46 Bn | 222.47 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.81 Bn | 178.63 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.28 Bn | 102.11 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.01 Bn | 47.63 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 674.00 Mn |
| Mar 31, 2026 | 645.00 Mn |
| Dec 31, 2025 | 715.00 Mn |
| Sep 30, 2025 | 808.00 Mn |
| Jun 30, 2025 | 582.00 Mn |
| Mar 31, 2025 | 737.00 Mn |
| Dec 31, 2024 | 833.00 Mn |
| Sep 30, 2024 | 903.00 Mn |
| Jun 30, 2024 | 537.00 Mn |
| Mar 31, 2024 | 622.00 Mn |
| Dec 31, 2023 | 550.00 Mn |
| Sep 30, 2023 | 586.00 Mn |
| Jun 30, 2023 | 622.00 Mn |
| Mar 31, 2023 | 627.00 Mn |
| Dec 31, 2022 | 905.00 Mn |
| Sep 30, 2022 | 614.00 Mn |
| Jun 30, 2022 | 565.00 Mn |
| Mar 31, 2022 | 583.00 Mn |
| Dec 31, 2021 | 705.00 Mn |
| Sep 30, 2021 | 585.00 Mn |